Upstream Bio, Stock Performance
| UPB Stock | 16.44 0.68 3.97% |
Upstream Bio, has a performance score of 1 on a scale of 0 to 100. The entity has a beta of -1.34, which indicates a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Upstream Bio, are expected to decrease by larger amounts. On the other hand, during market turmoil, Upstream Bio, is expected to outperform it. Upstream Bio, right now has a risk of 6.86%. Please validate Upstream Bio, skewness, and the relationship between the potential upside and rate of daily change , to decide if Upstream Bio, will be following its existing price patterns.
Risk-Adjusted Performance
1 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Upstream Bio, are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Upstream Bio, may actually be approaching a critical reversion point that can send shares even higher in February 2025. ...more
Actual Historical Performance (%)
One Day Return (3.97) | Five Day Return (16.55) | Ten Year Return (25.27) | All Time Return (25.27) |
1 | Upstream Bio shares soar in impressive IPO - The Pharma Letter | 10/14/2024 |
2 | Upstream bio director Erez Chimovits buys 14 million in shares | 10/17/2024 |
3 | This Eaton Analyst Begins Coverage On A Bullish Note Here Are Top 5 Initiations For Tuesday | 11/05/2024 |
4 | Upstream Bio Advances Clinical Trials, Strengthens Financials - TipRanks | 11/08/2024 |
5 | Upstream Bio Inc Joins Russell 2000 Index | 12/16/2024 |
6 | Upstream Bio Appoints Allison Ambrose as General Counsel | 12/17/2024 |
Upstream |
Upstream Bio, Relative Risk vs. Return Landscape
If you would invest 1,700 in Upstream Bio, on October 4, 2024 and sell it today you would lose (56.00) from holding Upstream Bio, or give up 3.29% of portfolio value over 90 days. Upstream Bio, is generating 0.171% of daily returns assuming volatility of 6.8597% on return distribution over 90 days investment horizon. In other words, 61% of stocks are less volatile than Upstream, and above 97% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Upstream Bio, Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Upstream Bio,'s investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Upstream Bio,, and traders can use it to determine the average amount a Upstream Bio,'s price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0249
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | UPB | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 6.86 actual daily | 61 61% of assets are less volatile |
Expected Return
| 0.17 actual daily | 3 97% of assets have higher returns |
Risk-Adjusted Return
| 0.02 actual daily | 1 99% of assets perform better |
Based on monthly moving average Upstream Bio, is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Upstream Bio, by adding it to a well-diversified portfolio.
About Upstream Bio, Performance
By analyzing Upstream Bio,'s fundamental ratios, stakeholders can gain valuable insights into Upstream Bio,'s financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Upstream Bio, has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Upstream Bio, has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Upstream Bio, is entity of United States. It is traded as Stock on NASDAQ exchange.Things to note about Upstream Bio, performance evaluation
Checking the ongoing alerts about Upstream Bio, for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Upstream Bio, help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Upstream Bio, had very high historical volatility over the last 90 days | |
| Latest headline from gurufocus.com: Upstream Bio Appoints Allison Ambrose as General Counsel |
- Analyzing Upstream Bio,'s financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Upstream Bio,'s stock is overvalued or undervalued compared to its peers.
- Examining Upstream Bio,'s industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Upstream Bio,'s management team can have a significant impact on its success or failure. Reviewing the track record and experience of Upstream Bio,'s management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Upstream Bio,'s stock. These opinions can provide insight into Upstream Bio,'s potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Upstream Stock analysis
When running Upstream Bio,'s price analysis, check to measure Upstream Bio,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Upstream Bio, is operating at the current time. Most of Upstream Bio,'s value examination focuses on studying past and present price action to predict the probability of Upstream Bio,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Upstream Bio,'s price. Additionally, you may evaluate how the addition of Upstream Bio, to your portfolios can decrease your overall portfolio volatility.
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Stocks Directory Find actively traded stocks across global markets | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |